Handelsbanken Fonder AB reduced its stake in Vertex Pharmaceuticals by 28.1% in Q4, selling 115,479 shares. The fund now owns ...

Makers of copycat versions of Novo Nordisk's (NVO) weight-loss drug semaglutide, also known as Ozempic and Wegovy, are suing ...

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...

Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird Bio for about $29 million.

Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 5.86% on an annualized basis producing an average annual return of 17.7%. Currently, Vertex Pharmaceuticals has a ...

Mirum gained the drug, which it will sell as Ctexli for adults with cerebrotendinous xanthomatosis, in a 2023 deal with ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.

An approval for the first drug for a rare lipid storage disease, some FDA workers rehired, and other biotech news of the day ...

A young Peninsula drugmaker won regulatory approval Friday for a rare-disease drug picked up in a deal two years ago.

The Trump administration has started quietly rehiring some of the U.S. Food and Drug Administration employees it fired last week, according to nine agency sources, shortly after letting them go in a ...

Mirum Pharmaceuticals (MIRM) announced that the FDA has approved Ctexli tablets, a bile acid, for the treatment of adults with cerebrotendinous ...

Ctexli’s approval further entrenches Mirum as a leader in rare liver diseases, alongside its cornerstone product Livmarli and ...